Alicia Algeciras-Schimnich, Ph.D., discusses how Mayo Clinic Laboratories’ new noninvasive blood test for Alzheimer’s disease identifies the p-tau217 biomarker, which is associated with the accumulation of amyloid beta in the brain. Positive test results can facilitate access to disease-modifying therapies. 

(00:32):

Dr. Algeciras, could you just provide a little bit of background on your role at Mayo Clinic?

(01:45):

So before we get into the test itself, can you just explain a little bit about the disease state and especially some of the recent changes?

(07:39)
 So can you explain a little bit more about what the results that our clients will receive look like?

(10:30)
 Can you just give a quick overview of how our test is unique compared to those on the market?

(12:24)
 What patients should have this testing performed, Dr. Algeciras and if you have any tips on which patients should not, please include that as well?

(14:42)
 Let's talk now about how those results are used in patient care.

(16:31)
 One more question, just summarize for our listeners what you're most excited about with this new test.